Skip to main content
    T

    Tango Therapeutics Inc (TNGX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $21.50
    +0.63 (+3.02%)

    Market Cap: $3.91B

    Last updated: Nov 06, 2026 at 4:29 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    59%(13/22)
    Avg Surprise
    +23.33%
    Streak
    1 Q

    Upcoming Estimates

    Period ending Dec 31, 2026
    EPS Consensus$-0.41
    Range$-0.58 - $-0.18
    12 analysts
    Revenue Consensus
    $-578090
    Range$-578090 - $-578090
    12 analysts
    Last 12 of 26 reported quarters and 1 upcoming estimate
    PeriodReportedEst.RangeSurpriseB/MAnalystsRevisionsYoY
    Dec 26EST
    		-$-0.41$-0.58 - $-0.18--12--
    Sep 26
    Reported Nov 3
    		$0.13N/A-+138.24%Beat12
    1
    2
    30d
    		+0.0%
    Jun 26
    Reported Aug 10
    		$-0.37$-0.31$-0.35 - $-0.30-19.35%Miss11
    3
    1
    30d
    		-5.7%
    Mar 26
    Reported May 13
    		$-0.32$-0.30$-0.38 - $-0.28-7.85%Miss11
    0
    1
    30d
    		+11.1%
    Dec 25
    Reported Mar 5
    		$-0.29$-0.33$-0.52 - $-0.24+12.12%Beat9
    2
    0
    30d
    		+14.7%
    Sep 25
    Reported Nov 4
    		$0.13$-0.07$-0.40 - $0.13+285.71%Beat8
    5
    0
    30d
    		+148.1%
    Jun 25
    Reported Aug 5
    		$-0.35$-0.34$-0.40 - $-0.27-2.94%Miss8
    1
    0
    30d
    		-45.8%
    Mar 25
    Reported May 12
    		$-0.36$-0.35$-0.38 - $-0.28-2.86%Miss7
    0
    1
    30d
    		-2.9%
    Dec 24
    Reported Feb 27
    		$-0.34$-0.34$-0.37 - $-0.25+0.82%Beat9
    5
    1
    30d
    		-6.3%
    Sep 24
    Reported Nov 6
    		$-0.27$-0.37$-0.52 - $-0.30+27.03%Beat10
    No revisions (30d)
    		-17.4%
    Jun 24
    Reported Aug 7
    		$-0.24$-0.35$-0.46 - $-0.29+31.43%Beat10
    1
    0
    30d
    		-4.3%
    Mar 24
    Reported May 8
    		$-0.35$-0.31$-0.33 - $-0.28-12.90%Miss9
    No revisions (30d)
    		-9.4%
    Dec 23
    Reported Mar 18
    		$-0.32$-0.28$-0.32 - $-0.25-14.29%Miss8
    No revisions (30d)
    		+3.0%

    Key Metrics

    Valuation
    P/E Ratio-25.29EV/EBITDAN/A
    Price/FCF-22.33xFCF Yield-4.48%
    Profitability
    Profit Margin-229.90%Operating Margin-253.40%
    ROE-21.30%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest Coverage15.27x
    Current Ratio50.82xQuick Ratio50.82x
    Trading Statistics
    Beta1.22Avg Volume4.43M
    52-Week High$34.3952-Week Low$7.49

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$22.30
    SMA 20$23.17
    SMA 50$23.34
    SMA 200$22.57
    EMA 10$22.44
    EMA 20$22.90
    EMA 50$23.63
    EMA 200$21.57

    MACD

    Line: -0.50Signal: -0.30Hist: -0.21

    ADX

    ADX: 10.4+DI: 18.5-DI: 22.2

    Aroon & PSAR

    Aroon Up56.0
    Aroon Down100.0
    PSAR$25.55

    Bollinger Bands

    Upper Band$26.68
    Lower Band$19.66
    %B Position3032%(Upper)
    Band Width0.26

    RSI (14-Day)

    Neutral
    43.9

    Momentum Oscillators

    Stoch %K11.6
    Stoch %D14.8
    Williams %R-89.8
    ROC (10d)-7.9%
    Momentum-1.84
    CCI (20d)-113.3
    MFI (14d)41.8

    Volatility Measures

    ATR (14d)$1.86(8.7%)
    StdDev (20d)1.76
    Hist Vol97.8%(High)

    Volume Flow

    VWAP$21.45
    OBV155.4M
    AD Line-15.3M
    CMF (20d)-0.170

    Volume Metrics

    Avg Vol (20d)4.5M
    Vol Ratio0.5x(Low)
    VWMA (20d)$23.32

    Pivot Points

    R3$25.50
    R2$24.54
    R1$22.70
    Pivot Point$21.74
    S1$19.91
    S2$18.95
    S3$17.11

    Advanced Oscillators

    TSI-7.09
    Ultimate Osc36.8
    KST-28.32

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$53.81M$3.18M$5.39M$4.12M$11.61M$19.88M$6.47M$5.43M$10.73M
    Cost of Revenue$0$0$479,000$0$0$0$620,000$0$0$0$617,000$0
    Gross Profit$0$0$-479,000$53.81M$3.18M$5.39M$4.12M$11.61M$19.88M$6.47M$5.43M$10.73M
    Operating Expenses$59.78M$48.77M$41.86M$39.74M$44.15M$47.92M$45.03M$44.48M$49.43M$48.73M$40.45M$36.36M
    R&D$37.20M$33.53M$32.10M$30.82M$32.81M$36.44M$33.94M$33.26M$38.65M$38.06M$31.34M$27.15M
    SG&A$22.59M$15.23M$9.76M$8.92M$11.34M$11.48M$11.09M$11.22M$10.77M$10.66M$9.11M$9.21M
    Operating Income$-59,785,000$-48,769,000$-41,864,000$14.07M$-40,967,000$-42,530,000$-40,910,000$-32,878,000$-29,552,000$-42,255,000$-35,014,000$-25,626,000
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$-3,723,000$-2,177,000$-1,680,000$-1,097,000$-1,239,000$-1,614,000$-1,813,000$-1,809,000$-2,071,000$-2,197,000$-2,236,000$-1,872,000
    Income Before Tax$-55,340,000$-45,513,000$-38,804,000$15.87M$-38,818,000$-39,842,000$-37,621,000$-29,113,000$-25,486,000$-37,874,000$-30,716,000$-22,240,000
    Income Tax Expense$1,000$1,000$-55,000$-10,000$35,000$34,000$49,000$54,000$65,000$40,000$47,000$23,000
    Net Income$-55,341,000$-45,514,000$-38,749,000$15.88M$-38,853,000$-39,876,000$-37,670,000$-29,167,000$-25,551,000$-37,914,000$-30,763,000$-22,263,000
    EBITDA$-58,638,000$-47,227,000$-40,005,000$15.33M$-39,432,000$-40,834,000$-38,814,000$-30,300,000$-26,925,000$-39,446,000$-32,335,000$-23,499,000
    EBIT$-59,063,000$-47,690,000$-40,484,000$14.78M$-40,057,000$-41,456,000$-39,434,000$-30,922,000$-27,557,000$-40,071,000$-32,952,000$-24,112,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about TNGX

    News

    Tango Therapeutics president sells $112,107 in shares By Investing.com

    Adam Crystal, President of Research & Development at Tango Therapeutics, sold 5,000 shares of the company's common stock for $112,107 on November 2, 2026, as part of a pre-arranged trading plan. Prior to the sale...

    Investing.com India•11/5/26•Somewhat-Bullish

    Tango Therapeutics, Inc. (TNGX) stock price, news, quote and history

    Tango Therapeutics, Inc. (TNGX) stock is currently trading at $24.35, down 12.82%, with market data experiencing temporary delays. The company, a precision oncology firm, is developing several drugs for various cancers...

    Yahoo Finance Singapore•11/5/26•Somewhat-Bearish

    Tango Therapeutics president sells $112,107 in shares

    Adam Crystal, President of Research & Development at Tango Therapeutics, sold 5,000 shares of the company's common stock for $112,107 on November 2, 2026, as part of a pre-arranged trading plan. Prior to this...

    Investing.com•11/4/26•Somewhat-Bullish

    Form 4 Tango Therapeutics Inc: Adam Crystal (President, R&D) For: 2 November By Investing.com

    This article reports on a Form 4 filing for Tango Therapeutics Inc, specifically detailing an insider transaction involving Adam Crystal, the President of Research & Development...

    Investing.com India•11/4/26•Neutral

    Form 4 Tango Therapeutics, Inc. For: Nov 02 Filed by: Newcomb Jessica

    Jessica Newcomb, Principal Accounting Officer at Tango Therapeutics, Inc. (TNGX), filed a Form 4 detailing transactions on November 2...

    StreetInsider•11/4/26•Somewhat-Bearish

    TNGX Valuation and Fair Value

    P/E
    -25.3x
    P/FCF
    -22.3x
    P/B
    3.1x
    See GNG's fair value

    TNGX Profitability: Margins, ROIC and FCF

    Operating margin
    -253.4%
    Net margin
    -229.9%
    ROE
    -21.3%
    FCF yield
    -4.5%

    TNGX Competitors

    CompanyTicker
    Iovance Biotherapeutics IncIOVA
    Catalyst Pharmaceuticals IncCPRX
    Envista Holdings CorpNVST
    Xenon Pharmaceuticals IncXENE
    Pulse Biosciences IncPLSE
    Organon & CoOGN
    Premier IncPINC
    Stevanato Group SpASTVN

    Sector: Healthcare

    TNGX Analyst Ratings

    Consensus
    Buy
    Analysts
    12
    Strong Buy
    1
    Buy
    10
    Hold
    1
    Sell
    0
    Strong Sell
    0

    TNGX Bull Case vs Bear Case

    Bull case

    • 91.7% of TNGX's analyst ratings are Buy or Strong Buy.

    Bear case

    • TNGX has a -229.9% net profit margin.
    • TNGX's quarterly revenue changed -100.0% year over year.

    TNGX Earnings: Beat Rate and Next Report

    Beat rate
    4 of 8 quarters (50.0%)
    Average surprise
    50.5%
    EPS estimate (fiscal period ending Dec 31, 2026)
    $-0.41

    TNGX Earnings Date

    TNGX reports Mar 3, 2027, after the close. The date is estimated.

    TNGX ETF Holders

    GNG tracks 9 ETFs that hold TNGX. The largest weights:

    1. State Street SPDR S&P Biotech ETF (XBI), 0.88% of the fund
    2. First Trust Small Cap Growth AlphaDEX Fund (FYC), 0.41% of the fund
    3. iShares Biotechnology ETF (IBB), 0.22% of the fund
    4. Fidelity Enhanced Small Cap Core ETF (FESM), 0.16% of the fund
    5. Vanguard Health Care Index Fund ETF Shares (VHT), 0.03% of the fund
    Open the ETF Stock Exposure tool for TNGX

    See insider activity

    Frequently Asked Questions About TNGX

    When does TNGX report earnings?

    Tango Therapeutics Inc (TNGX) is expected to report earnings on Mar 3, 2027.

    Does TNGX pay dividends?

    Tango Therapeutics Inc (TNGX) does not currently pay a regular dividend.

    What is TNGX's market cap?

    Tango Therapeutics Inc (TNGX) has a market capitalization of $3.91B with a current stock price of $21.50.

    Related stocks

    Sector: Healthcare

    All stocks starting with T

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In